

Methodological Index for Non-Randomized Studies (MINORS)

Study: **Sundlöv et al. (2022) - ILUMINET trial**

Total Score: 14/16 (High methodological quality).

Methodological item (MINORS)	Score (0-2)	Support for judgment
1. A clearly stated aim	2	The aim is clearly stated: to evaluate individualized ¹⁷⁷ Lu-DOTATATE treatment in which the number of cycles varied based on renal dosimetry.
2. Inclusion of consecutive patients	1	97 patients were enrolled over a specific timeframe (Oct 2011 to Jun 2018). While this implies a continuous enrollment process, the specific term 'consecutive' is not explicitly used by the authors.
3. Prospective collection of data	2	The study is a prospectively registered, single-arm phase II trial (NCT01456078, EudraCT 2011-000240-16).
4. Endpoints appropriate to the aim of the study	2	The endpoints are standard and highly appropriate for PRRT evaluation: primary endpoint was objective tumor response (RECIST 1.1), secondary endpoints were PFS, OS, and toxicity.
5. Unbiased assessment of the study endpoint	1	Tumor response was evaluated using objective criteria (RECIST 1.1). However, the study utilized an open-label design and did not explicitly mention the use of a Blinded Independent Central Review (BICR) for imaging assessment.

6. Follow-up period appropriate to the aim of the study	2	The median follow-up time was 42 months, which is highly sufficient to observe both long-term survival outcomes (PFS/OS) and late-onset toxicities (e.g., late renal impairment).
7. Loss to follow up less than 5%	2	All 96 treated patients were fully followed and evaluated for overall survival (OS) and toxicity (loss to follow-up for OS = 0%).
8. Prospective calculation of the study size	2	A clear statistical power calculation was provided: 100 patients were required to obtain a 95% confidence interval with a 10% margin of error, assuming an expected objective response rate of 20-40%.